VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | Insights into the Phase II TIDAL study

Tycel Phillips, MD, City of Hope, Duarte, CA, shares some insights into the Phase II TIDAL study (NCT03768505), which is evaluating the safety and efficacy of zandelisib in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL) who have failed at least two prior lines of therapy. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter